Patents by Inventor Carl H. June

Carl H. June has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ICOS Critically Regulates the Expansion and Function of Inflammatory Human Th17 Cells
    Publication number: 20150342994
    Abstract: The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
    Type: Application
    Filed: August 11, 2015
    Publication date: December 3, 2015
    Inventors: James L. Riley, Chrystal Paulos, Carl H. June, Bruce L. Levine
  • Enhancing Activity of CAR T Cells by Co-Introducing a Bispecific Antibody
    Publication number: 20150322169
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a T cell, genetically modified to express a chimeric antigen receptor (CAR), a bispecific antibody, or a combination thereof to a subject. The CAR and bispecific antibody of the invention can comprise a human antibody, a humanized antibody, or antigen-binding fragments thereof.
    Type: Application
    Filed: July 12, 2013
    Publication date: November 12, 2015
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Yangbing Zhao, Xiaojun Liu
  • Method for treating chronic lymphocytic leukemia (CC)
    Patent number: 9161971
    Abstract: The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: October 20, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce Levine, Anne Chew, Stephen J. Schuster
  • USE OF CART19 TO DEPLETE NORMAL B CELLS TO INDUCE TOLERANCE
    Publication number: 20150290244
    Abstract: The present invention provides compositions and methods for inducing tolerance in a human. The invention includes administering a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: July 12, 2013
    Publication date: October 15, 2015
    Inventors: Carl H. June, Bruce L. Levine, Michael D. Kalos
  • TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20150283178
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
    Type: Application
    Filed: April 7, 2015
    Publication date: October 8, 2015
    Inventors: Carl H. June, David L. Porter, Marcela Maus, Mariusz Wasik, Saar Gill, Joseph Fraietta, Marco Ruella, John Byrd, Jason Dubovsky, Amy Johnson, Natarajan Muthusamy, Saad Kenderian, Joan Mannick, David Glass, Leon Murphy, Jennifer Brogdon, William Raj Sellers
  • ICOS critically regulates the expansion and function of inflammatory human Th17 cells
    Patent number: 9133436
    Abstract: The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: September 15, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James L. Riley, Chrystal Paulos, Carl H. June, Bruce Levine
  • Compositions for treatment of cancer
    Patent number: 9102760
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: August 11, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Methods for treatment of cancer
    Patent number: 9101584
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: August 11, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Compositions for treatment of cancer
    Patent number: 9102761
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: August 11, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Toxicity Management for Anti-Tumor Activity of CARs
    Publication number: 20150202286
    Abstract: The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient.
    Type: Application
    Filed: July 12, 2013
    Publication date: July 23, 2015
    Applicant: The Children's Hospital of Philadelphai
    Inventors: Carl H. June, Bruce L. Levine, Michael D. Kalos, Stephan Grupp
  • Methods for Assessing the Suitability of Transduced T Cells for Administration
    Publication number: 20150190428
    Abstract: The invention relates to of analyzing vector supernatants useful for transducing T cells destined for administration to a human subject. The invention also related to methods of analyzing transduced T cells destined for administration to a human subject.
    Type: Application
    Filed: July 12, 2013
    Publication date: July 9, 2015
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, Michael D. Kalos
  • Compositions and Methods for Regulating CAR T Cells
    Publication number: 20150140019
    Abstract: The present invention provides compositions and methods for inhibiting the depletion of healthy tissue during CAR T cell therapy. In another embodiment, the invention includes a drug-molecule conjugate which is administered to a subject receiving CAR T cell therapy, where the conjugate binds to the CAR resulting in internalization of the conjugate and inhibition of T cell activity and/or death of the T cell.
    Type: Application
    Filed: July 12, 2013
    Publication date: May 21, 2015
    Inventors: Carl H. June, Bruce L. Levine, Michael D. Kalos
  • Methods for Treatment of Cancer
    Publication number: 20150118202
    Abstract: The present invention provides compositions and methods for treating cancer in a human.
    Type: Application
    Filed: December 12, 2014
    Publication date: April 30, 2015
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Compositions for Treatment of Cancer
    Publication number: 20150099299
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: December 12, 2014
    Publication date: April 9, 2015
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Compositions for Treatment of Cancer
    Publication number: 20150093822
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: December 11, 2014
    Publication date: April 2, 2015
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Compositions for treatment of cancer
    Patent number: 8975071
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: March 10, 2015
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Compositions for Treatment of Cancer
    Publication number: 20150050729
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Application
    Filed: August 22, 2014
    Publication date: February 19, 2015
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Compositions and Methods for Generating a Persisting Population of T Cells Useful for the Treatment of Cancer
    Publication number: 20150024482
    Abstract: The present invention provides compositions and methods for generating a genetically modified T cells comprising a chimeric antigen receptor (CAR) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.
    Type: Application
    Filed: February 22, 2013
    Publication date: January 22, 2015
    Inventors: Matthew J. Frigault, Yangbing Zhao, John Scholler, Carl H. June
  • USE OF ICOS-BASED CARS TO ENHANCE ANTITUMOR ACTIVITY AND CAR PERSISTENCE
    Publication number: 20150017141
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a genetically modified Th17 cell to express a CAR having an antigen binding domain, a transmembrane domain, and an ICOS intracellular signaling domain.
    Type: Application
    Filed: February 22, 2013
    Publication date: January 15, 2015
    Applicant: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Sonia Guedan Carrio, Yangbing Zhao, John Scholler
  • Methods for treatment of cancer
    Patent number: 8916381
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: December 23, 2014
    Assignee: The Trustees of the University of Pennyslvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone